MedTrace Logo

Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose

NCT02811185 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1012

Last updated 2017-05-04

No results posted yet for this study

Summary

This is a single-centre, open-label, non-randomized clinical trial designed to monitor the occurrence of adverse events associated with \[F-18\]-FDG Injection manufactured by the Fedoruk Centre. \[F-18\]-FDG Injection used in this clinical trial will be identical to commercial \[F-18\]-FDG that is already used at Royal University Hospital (RUH).

Conditions

  • Positron-Emission Tomography and Cone-Beam Computed Tomography

Interventions

DRUG

[F-18]-Fludeoxyglucose

Radiopharmaceutical imaging agent

Sponsors & Collaborators

  • Sylvia Fedoruk Canadian Centre for Nuclear Innovation

    collaborator OTHER

  • Saskatoon Health Region

    collaborator OTHER

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Rajan Rakheja, MD · Saskatoon Health Region

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-01-31
Completion
2017-01-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02811185 on ClinicalTrials.gov